Primary thrombocythaemia following splenectomy

J. R. O’DONNELL*
M.B., Ch.B., M.R.C.P.I.

P. A. M. BAILEY†
B.A., M.B., Ch.B., M.R.C.Path.

J. G. ERSKINE*
M.B., Ch.B., M.R.C.P.(UK), M.R.C.Path.

J. F. DAVIDSON*
M.B., Ch.B., F.R.C.P.(Edin.), M.R.C.Path.

Departments of Haematology, *Glasgow Royal Infirmary, and †Dumfries and Galloway Royal Infirmary

Summary
A 20-year-old male who required splenectomy following abdominal trauma was subsequently shown to have primary thrombocythaemia. This report illustrates the diagnostic problems associated with a refractory post-splenectomy thrombocytosis, and the therapeutic difficulties in the management of primary thrombocythaemia are discussed.

Introduction
Primary thrombocythaemia (PT) is a well recognized syndrome within the spectrum of myeloproliferative disorders. Typically presenting from middle-age onwards, difficulties may arise in differentiation from secondary thrombocytosis or other myeloproliferative states particularly in younger patients. This report of an unusual presentation of PT in a 20-year-old male demonstrates some of the problems associated with the diagnosis and management of the disorder.

Case report
A 20-year-old healthy male who had worked for 4 years in a nuclear reactor plant was involved in a road traffic accident and required a laparotomy because of intra-abdominal trauma. At operation a large haemoperitoneum consequent upon a ruptured spleen was found and splenectomy was performed. The spleen was noted to be enlarged, weighing 425 g, and operative blood loss was copious, being estimated at > 3 litres. Immediate postoperative progress was uncomplicated. A pre-operative blood count was not available and so a platelet count of 1016 x 10⁹/l, immediately following splenectomy appeared unremarkable. Over the next 10 days the platelet count rose progressively to 3472 x 10⁹/l. The thrombocytosis was assumed to be an unusually marked reactive response following trauma and splenectomy and was expected to subside rapidly. Oral salicylate therapy was, however, started as prophylaxis against possible thrombotic complications.

Over the next 6 weeks the platelet count remained markedly elevated between 2976 x 10⁹/l and 3312 x 10⁹/l, although the patient remained asymptomatic. Because of persistent marked thrombocytosis further investigations were initiated. Serial platelet counts over 7 days ranged from 2950 x 10⁹/l to 4410 x 10⁹/l (mean value 3760 x 10⁹/l). Haemoglobin levels were normal. There was a leucocytosis of 18-9 x 10⁹/l to 21-9 x 10⁹/l (approximately 70% polymorphs). Blood films showed post-splenectomy changes with marked variation in platelet morphology and occasional megakaryocyte fragments. Sternal bone marrow aspirate revealed an extremely hypercellular marrow. Granulopoiesis was hyperplastic and there was a gross increase in megakaryocytes which formed distinct clumps. Many giant megakaryocytes were noted showing nuclear hyperplody. A bone biopsy was followed by profuse bleeding for several hours from the posterior iliac crest site. Histology showed a similar picture to the marrow aspirate with large clumps of megakaryocytes. There was no significant increase in reticulin. Chromosome analysis showed a normal male karyotype. Leucocyte alkaline phosphatase score was normal as were blood volume studies and serum vitamin B₁₂ assay. Platelet function tests revealed only salicylate inhibition of aggregation. Biochemical investigations showed hyperkalaemia of 6-4 mmol/l, hyperuricaemia of 450 μmol/l and a slightly elevated lactic dehydrogenase of 886 u/l. Blood volume studies were not performed.

The diagnosis of primary thrombocythaemia was well established despite the unusual age and presentation of the patient. Radioactive phosphorus, 3 mCi, was administered and salicylate therapy was continued. The platelet count had fallen to 1808 x 10⁹/l after 2 months but rose over the following month to 2544 x 10⁹/l. A further 2 mCi of radioactive phosphorus were administered and within 6 weeks

0032-5473/81/0800-0532 $02.00 © 1981 The Fellowship of Postgraduate Medicine
the platelet count had fallen (1228 × 10^9/l). However, one month later the count had risen to 2032 × 10^9/l.

**Discussion**

The distinction between primary thrombocythaemia and a reactive thrombocytosis may often prove difficult. However, a platelet count in excess of 2000 × 10^9/l for >2 months after splenectomy is highly suggestive of primary thrombocythaemia (Williams, 1977). A lesser degree of thrombocytosis (up to 1000 × 10^9/l) may persist for longer periods in patients where anaemia continues following splenectomy (Hirsh and Dacie, 1966). Post-splenectomy thrombocytosis could therefore be dismissed as simply reactive, although it has been reported that splenectomy can uncover unrecognized primary thrombocythaemia (Hardisty and Wolff, 1955; Bensinger, Logue and Rundles, 1970).

This case clearly showed the diagnostic problem with primary thrombocythaemia, especially in very young patients. However, the degree and duration of the thrombocytosis combined with the very characteristic morphological appearances and signs of increased cell turnover are virtually diagnostic of primary thrombocythaemia. Although accurate platelet counting is difficult at such concentrations, the inhibitory effect of salicylates on platelet aggregation may have aided counting reproducibility. Unfortunately, this effect also prevented demonstration of the abnormalities of platelet function known to occur in primary thrombocythaemia (Hardisty and Wolff, 1955; McClure et al., 1966).

Information regarding the natural history of primary thrombocythaemia is scanty, but significant morbidity and mortality from thrombosis and/or haemorrhage has been recorded, especially following splenectomy (Gunz, 1960; Silverstein, 1968). Because of that risk, salicylate therapy was instituted in this patient. Urgent myelosuppressive therapy has been advised in patients where primary thrombocythaemia becomes apparent after splenectomy, and agents such as radioactive phosphorus and cytotoxic drugs are effective for control of primary thrombocythaemia, particularly in the elderly (Bensinger et al., 1970). However, in the very young patient there is little indication from the few cases reported on the long-term efficacy or risks of myelosuppressive therapy. The response of the present patient to therapy with radioactive phosphorus has not been encouraging thus far.

Five cases of primary thrombocythaemia have been reported in patients under 20 years of age (Thieffry, Buhot and Aicardi, 1975; Levinson et al., 1958; Ozer et al., 1960; Spach, Howell and Harris, 1963; Fickers and Speck, 1974). The course in these young patients was very variable. One patient who presented at 8 years of age remained healthy without treatment 7 years after initial diagnosis of primary thrombocythaemia (Spach et al., 1963). However, 2 other patients developed acute myeloid leukaemia within 3 years of diagnosis, one after treatment with radioactive phosphorus, the other after chemotherapy with thiopeta and busulphan. Estimates vary widely on the frequency of blast transformation in myeloproliferative states (Ward and Block, 1971). The scarcity of reports on primary thrombocythaemia, especially in the young, makes it impossible to quantify this risk. An added problem is the requirement for myelosuppressive therapy, in itself almost certainly leukaemogenic.

This unusual case of primary thrombocythaemia with gross elevation of the platelet count following splenectomy in a very young patient illustrates some of the diagnostic and therapeutic difficulties in this disorder. As thrombocytosis is an expected post-splenectomy finding, close haematological monitoring of a prolonged thrombocytosis is essential to identify the rare patient with an underlying myeloproliferative disorder.

**References**


SILVERSTEIN, M.N. (1968) Primary or hemorrhagic thrombocythemia. *Archives of Internal Medicine*, 122, 18.


533
Primary thrombocythaemia following splenectomy

J. R. O'Donnell, P. A. M. Bailey, J. G. Erskine and J. F. Davidson

doi: 10.1136/pgmj.57.670.532

Updated information and services can be found at:
http://pmj.bmj.com/content/57/670/532

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/